Skip to main content
. 2017 Aug 1;83(11):2367–2376. doi: 10.1111/bcp.13351

Table 1.

Demographic characteristics of study participants

PRN1008 dose regimen: PART A
Parameter Statistic 50 mg 150 mg 300 mg 600 mg 1200 mg Placebo Total
Age (years)
N 6 6 6 6 6 10 40
Mean 24.8 28.0 20.5 26.3 32.2 22.9 25.5
SD 4.5 11.7 2.0 5.4 11.7 3.4 7.6
Median 23.5 23.5 21.5 25.5 29.0 23.0 23.0
Race
Caucasian n (%) 4 (67%) 4 (67%) 6 (100%) 6 (100%) 5 (83%) 9 (90%) 34 (85%)
Asian n (%) 1 (17%) 1 (17%) 1 (10%) 3 (8%)
Black n (%) 1 (17%) 1 (3%)
Other: Arabic n (%) 1 (17%) 1 (3%)
Other: Eurasian n (%) 1 (17%) 1 (3%)
Sex
Male n (%) 6 (100%) 6 (100%) 6 (100%) 6 (100%) 6 (100%) 10 (100%) 40 (100%)
Weight (kg)
Mean 74.1 73.1 80.8 74.0 86.0 74.1 76.7
SD 9.5 9.4 8.5 10.7 12.9 9.6 10.5
Median 76.2 75.4 78.4 74.0 79.4 76.3 77.1
BMI
Mean 22.7 23.1 24.2 23.5 26.2 22.5 23.6
SD 2.0 3.3 1.6 2.6 3.3 1.7 2.6
Median 23.2 23.5 23.9 22.8 25.2 22.1 23.5
PRN 1008 dose regimen: PART B
Parameter Statistic 300 mg QD 300 mg BID 600 mg QD 450 mg BID Placebo Total
Age (years)
N 8 8 8 8 8 40
Mean 30.0 27.0 23.6 28.9 24.4 26.8
SD 8.5 7.0 4.2 7.3 5.0 6.7
Median 27.0 25.5 23.5 27.5 23.0 24.0
Race
Caucasian n (%) 5 (63%) 7 (88%) 7 (88%) 6 (75%) 6 (75%) 31 (78%)
Asian n (%) 2 (25%) 1 (13%) 1 (13%) 1 (13%) 5 (13%)
Black n (%) 1 (13%) 1 (13%) 1 (13%) 3 (8%)
Other: Eurasian n (%) 1 (13%) 1 (3%)
Sex
Male n (%) 8 (100%) 8 (100%) 8 (100%) 8 (100%) 8 (100%) 40 (100%)
Weight (kg)
Mean 76.0 75.3 87.0 86.0 75.5 79.9
SD 10.2 12.3 15.2 12.7 10.3 12.8
Median 75.6 72.8 88.1 91.4 75.7 76.9
BMI
Mean 25.1 23.8 25.0 25.6 23.4 24.6
SD 2.4 4.0 3.4 3.1 2.3 3.1
Median 25.3 21.8 24.3 26.7 23.2 24.1

SD, standard deviation; BMI, body mass index; QD = every 24 h; BID = every 12 h